Literature DB >> 8281852

Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.

V Savarino1, G S Mela, P Zentilin, P Cutela, M R Mele, S Vigneri, G Celle.   

Abstract

This study was carried out in order to perform a combined prospective assessment of the individual pharmacodynamic response and of duodenal ulcer healing in patients treated with three different doses of omeprazole. Ninety-nine patients with endoscopically proven duodenal ulcers were subdivided into three parallel groups of 33 cases, who were randomly assigned to receive orally at 0800 hr, in single blind fashion, either 10 mg, 20 mg, or 40 mg of omeprazole. All of them underwent continuous intragastric pH monitoring both in basal conditions and on the fifth day of each dose regimen; ulcer healing was then assessed endoscopically after four weeks of treatment. All three doses of omeprazole caused pH values to increase significantly (P < 0.001) over the whole 24-hr period. In patients treated with omeprazole 10 mg, the individual responses showed the highest variability: the acid inhibition, expressed in terms of time spent above pH 3.0, lasted for more than 16 hr in 42% of cases, for more than 8 hr in 28%, and for less than 6 hr in 30%. In patients treated with omeprazole 20 mg, the pharmacological response was more marked and uniform and lasted for more than 16 hr in 79% of cases; however, it is worth noting it lasted for less than 6 hr in three patients (10%). In patients treated with omeprazole 40 mg, the individual response was excellent (more than 16 hr) in 94% of cases, and it lasted for less than 6 hr in only one patient (3%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8281852     DOI: 10.1007/BF02090077

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

Review 1.  Omeprazole.

Authors:  P N Maton
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

2.  U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

Authors:  J E Valenzuela; R G Berlin; W J Snape; T L Johnson; B I Hirschowitz; J Colon-Pagan; R S Morse; J Petrozza; G M Van Deventer; A Cagliola
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

3.  Clinical relevance of sampling rate in the characterization and analysis of 24-hour gastric acidity. A report on 413 cases.

Authors:  G S Mela; V Savarino; M Moretti; G Bonifacino; A Sumberaz; P Zentilin
Journal:  Scand J Gastroenterol       Date:  1989-08       Impact factor: 2.423

4.  Omeprazole versus placebo in duodenal ulcer healing. The United States experience.

Authors:  D Y Graham; A McCullough; M Sklar; S J Sontag; W M Roufail; R C Stone; R H Bishop; N Gitlin; A J Cagliola; R S Berman
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

5.  Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers.

Authors:  P J Prichard; D Rubinstein; D B Jones; F J Dudley; R A Smallwood; W J Louis; N D Yeomans
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-23

Review 6.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

7.  Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.

Authors:  V Savarino; G S Mela; P Zentilin; P Scalabrini; G Bonifacino; P Gambaro; G Celle
Journal:  Digestion       Date:  1989       Impact factor: 3.216

8.  Circadian pattern of intragastric acidity in duodenal ulcer patients: a study of variations in relation to ulcer activity.

Authors:  S Wagner; U Gladziwa; M Gebel; A Schüler; J Freise; F W Schmidt
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

9.  Continuous 24 hour intragastric pH monitoring: focus on reproducibility in duodenal ulcer patients. A preliminary report.

Authors:  V Savarino; G S Mela; P Scalabrini; M R Magnolia; E Di Timoteo; G Percario; G Celle
Journal:  Gastroenterol Clin Biol       Date:  1986-12

Review 10.  Effects of omeprazole on gastric secretory functions.

Authors:  H P Festen
Journal:  Digestion       Date:  1989       Impact factor: 3.216

View more
  5 in total

1.  Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.

Authors:  M L Cloud; N Enas; T J Humphries; S Bassion
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

2.  Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study.

Authors:  J Labenz; U Peitz; C Leusing; B Tillenburg; A L Blum; G Börsch
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

3.  Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.

Authors:  R H Holloway; J Dent; F Narielvala; A M Mackinnon
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

4.  Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer.

Authors:  V Savarino; G S Mela; P Zentilin; P Cutela; M R Mele; D Perilli; A Vassallo; A Zambotti; C Mansi; G Celle
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

5.  Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group.

Authors:  C M Bate; S N Booth; J P Crowe; R A Mountford; P W Keeling; B Hepworth-Jones; M D Taylor; P D Richardson
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.